表紙
市場調查報告書

DNA損害反應 (DDR) 抑制劑的全球市場 (2020-2030年):已上市藥、開發平台藥物

Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 955771
出版日期 內容資訊 英文 247 Pages
商品交期: 最快1-2個工作天內
價格
DNA損害反應 (DDR) 抑制劑的全球市場 (2020-2030年):已上市藥、開發平台藥物 Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日期: 2020年08月26日內容資訊: 英文 247 Pages
簡介

全球DNA損害反應 (DDR) 抑制劑的市場在預測期間內預計以21.33%的年複合成長率發展,市場規模2030年達到248億4880萬美元。癌症的盛行率的全球性上升,有利的償付方案,腫瘤領域的R&D支出的增加,癌症治療的精密醫療的引進擴大等要素促進該市場的成長。

本報告提供全球DNA損害反應 (DDR) 抑制劑的市場調查,市場定義和概要,癌症研究的DDR途徑的重要性,法律制度,COVID-19以及其他的市場影響因素分析,已上市藥及開發平台藥物概要,趨勢,市場規模的變化、預測,各開發階段、用途、地區/主要國家的詳細分析,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 市場概要

  • 癌症研究的DDR途徑的重要性
  • 標的化DDR途徑的主要策略
  • DDR醫藥品的商業化環境
  • COVID-19的影響
  • 市場規模、成長的潛在性:各地區

第5章 產業考察

  • 概要
  • 法律上的必要條件、架構:美國
  • 法律上的必要條件、架構:歐洲
  • 法律上的必要條件、架構:亞太地區
  • 專利分析

第6章 市場動態

  • 概要
  • 影響分析
  • 成長推動因素
  • 阻礙成長要素
  • 市場機會

第7章 競爭情形

  • 主要策略、展開
  • 市場佔有率分析
  • 成長佔有率分析:已上市藥

第8章 流行病學分析

第9章 臨床環境

  • 各階段
  • 各標的DDR途徑
  • 各癌症種類

第10章 市場分析、預測:已上市藥

  • 概要
  • Lynparza
  • Talzenna
  • Zejula
  • Rubraca

第11章 市場分析、預測:各開發平台藥物

  • 概要
  • PARP抑制劑
    • 階段III
    • 階段II
    • 階段I
  • WEE1激化酵素抑制劑
    • 階段I
  • ATR激化酵素抑制劑
    • 階段II
    • 階段I
  • Aurora B激化酵素抑制劑
    • 階段II
  • DNA-PK抑制劑
    • 階段II
    • 階段I
  • 其他
    • 階段II
    • 階段I

第12章 市場分析、預測:各用途

  • 概要
  • 卵巢癌
  • 乳癌
  • 胰臟癌
  • 前列腺癌

第13章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 瑞士
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他
  • 南美
    • 巴西
    • 其他
  • 其他地區

第14章 企業簡介

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene, Ltd.
  • Clovis Oncology
  • Debiopharm International SA
  • Eli Lilly & Company
  • GlaxoSmithKline plc
  • Merck KGaA
  • NMS Group S.p.A
  • Onxeo SA
  • Pfizer Inc.
  • Repare Therapeutics
  • Sierra Oncology, Inc.
  • Zentalis Pharmaceuticals, LLC
目錄
Product Code: BHP0942SA

"Global DNA Damage Response Drugs Market to Reach $24,848.8 Million by 2030."

Market Report Coverage - DNA Damage Response Drugs

Market Segmentation

  • Commercialized Drugs - Lynparza, Talzenna, Zejula, and Rubraca
  • Pipeline Analysis (by Mechanism of Action)- PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, and DNA-PK Inhibitor, and Others
  • Application - Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Rising Global Prevalence of Cancer
  • Favourable Regulatory Environment
  • Increasing Oncology R&D Expenditure
  • Increase in Adoption of Precision Medicine in Cancer Treatment

Market Challenges

  • High Cost Hindering the Adoption Rate
  • Unfavorable Reimbursement Scenario
  • Safety Concerns Pertaining to Severe Adverse Effects

Market Opportunities

  • Massive Scope in Emerging Regions

Key Companies Profiled

AbbVie Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd., Clovis Oncology, Debiopharm International SA, Eli Lilly & Company, GlaxoSmithKline plc, Merck KGaA, NMS Group S.p.A, Onxeo SA, Pfizer Inc., Repare Therapeutics, Sierra Oncology, Inc., and Zentalis Pharmaceuticals, LLC

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global DNA damage response drugs market?
  • What are the underlying structures resulting in the emerging trends within the global DNA damage response drugs market?
  • What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the DNA damage response drugs?
  • What is the pricing and reimbursement scenario for DNA damage response drugs market?
  • What is the implication of the COVID-19 pandemic on the oncology research?
  • What are the potential DNA damage response drugs present in the pipeline?
  • What is the clinical landscape of DNA damage response drugs market?
  • How is each segment of the market expected to grow during the forecast period from 2020 to 2030? What is the anticipated revenue to be generated by each of the segments on the basis of:
    • Commercialized Drugs (Lynparza, Talzenna, Zujula, and Rubraca)
    • Potential Pipeline Drugs (PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, DNA-PK Inhibitor, and Others)
    • Application (Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • Who are the leading players with significant offerings to the global DNA damage response drugs market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the current treatment gaps, and how are DNA damage response drugs anticipated to fill these gaps?
  • How does cancer burden impact the development of DNA damage response drugs worldwide?
  • What are the unmet needs that are currently being faced?

Market Overview

Our healthcare experts have found DNA damage response drugs industry to be one of the most rapidly evolving markets. The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.

The market is favored by the developments in the field of oncology research for discovering underlying molecular mechanisms of cancerous cells for the development of novel therapeutics. Moreover, the growing cases of advanced cancer worldwide has significantly escalated the need for developing DNA damage response drugs for solving cancer unmet needs. These drugs have unprecedented potential in terms of offering a selective and efficient tolerated treatment approach for improving cancer survival rates.

Within the research report, the market is segmented on the basis of commercialized drugs, pipeline analysis (by mechanism of action), application, and region. The commercialized drugs segment contains the revenue which is expected to be generated by the successful launch of commercialized drugs that are in Phase III clinical trials and are being evaluated for other cancer indications based on different biomarkers. The pipeline analysis (by mechanism of action) segment covers non-commercialized DNA damage response drugs that are currently in Phase III clinical trials and are being developed as a monotherapy treatment for various cancer indications. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among the pharmaceutical companies to invest in the development of small molecule cancer drugs. Due to the diverse product and pipeline portfolio and intense market penetration, AstraZeneca plc has been a pioneer in this field and has been a significant competitor in this market.

Several other companies such as GlaxoSmithKline plc, Pfizer Inc., and Clovis Oncology, have also launched their respective DNA damage response drugs, such as Zejula, Talzenna, and Rubraca, respectively, to compete with Lynparza's market dominance.

On the basis of region, North America holds the largest share of DNA damage response drugs market due to the availability of capital and cancer research expertise, growing need to develop novel cancer therapeutics, and high adoption of precision medicine, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 DNA Damage Response Drugs in Oncology: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Market Overview

  • 4.1 Introduction
  • 4.2 Importance of DDR Pathways in Oncology
  • 4.3 Key Strategies for Targeting DDR Pathways
  • 4.4 DDR Drugs Commercialization Landscape
  • 4.5 COVID-19 Impact on Oncology Clinical Research
  • 4.6 Market Size and Growth Potential, $Million, 2019-2030
    • 4.6.1 North America
    • 4.6.2 Europe
    • 4.6.3 Asia-Pacific (APAC)
    • 4.6.4 Latin America (LATAM)
    • 4.6.5 Rest-of-the-World (RoW)

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Frameworks in the U.S.
    • 5.2.1 Clinical Trial Authorization
    • 5.2.2 Marketing Authorization
    • 5.2.3 Post-Authorization Regulations
  • 5.3 Legal Requirements and Frameworks in Europe
    • 5.3.1 Centralized Procedure
    • 5.3.2 Decentralized Procedure
    • 5.3.3 Mutual-Recognition Procedure
    • 5.3.4 National Procedure
  • 5.4 Legal Requirements and Frameworks in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan
  • 5.5 Patent Analysis

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Rising Global Prevalence of Cancer
    • 6.3.2 Favorable Regulatory Environment
    • 6.3.3 Increasing Oncology R&D Expenditure
    • 6.3.4 Increase in Adoption of Precision Medicine in Cancer Treatment
  • 6.4 Market Restraints
    • 6.4.1 High Cost Hindering the Adoption Rate
    • 6.4.2 Unfavorable Reimbursement Scenario
    • 6.4.3 Safety Concerns Pertaining to Severe Adverse Effects
  • 6.5 Market Opportunity
    • 6.5.1 Massive scope in Emerging Regions

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Product Approvals and Other Activities
    • 7.1.2 Synergistic Activities
    • 7.1.3 Product Launch and Updradations
    • 7.1.4 Business Expansion and Funding
    • 7.1.5 Mergers and Acquisitions
  • 7.2 Market Share Analysis, 2018-2019
  • 7.3 Growth Share Analysis (by Commercialized Drugs)

8 Epidemiology Analysis for DNA Damage Response Drugs

9 Clinical Landscape

  • 9.1 By Phase of Development
  • 9.2 By DDR Pathway Target
  • 9.3 By Oncology Specialty

10 Global DNA Damage Response Drugs Market, by Commercialized Drugs ($Million), 2019-2030

  • 10.1 Overview
  • 10.2 Lynparza
  • 10.3 Talzenna
  • 10.4 Zejula
  • 10.5 Rubraca

11 DNA Damage Response Drugs, by Potential Pipeline Drugs

  • 11.1 Overview
  • 11.2 PARP Inhibitor
    • 11.2.1 Phase III
      • 11.2.1.1 Pamiparib
      • 11.2.1.2 Veliparib
      • 11.2.1.3 Fluzoparib
    • 11.2.2 Phase II
    • 11.2.3 Phase I
  • 11.3 WEE1 Kinase Inhibitor
    • 11.3.1 Phase I
  • 11.4 ATR Kinase Inhibitor
    • 11.4.1 Phase II
    • 11.4.2 Phase I
  • 11.5 Aurora B Kinase Inhibitor
    • 11.5.1 Phase II
  • 11.6 DNA-PK Inhibitors
    • 11.6.1 Phase II
    • 11.6.2 Phase I
  • 11.7 Others
    • 11.7.1 Phase II
    • 11.7.2 Phase I

12 Global DNA Damage Response Drugs Market, by Application, ($Million), 2019-2030

  • 12.1 Overview
  • 12.2 Ovarian Cancer
  • 12.3 Breast Cancer
  • 12.4 Pancreatic Cancer
  • 12.5 Prostate Cancer

13 Global DNA Damage Response Drugs Market, by Region ($Million), 2019-2030

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 France
    • 13.3.3 U.K.
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Switzerland
    • 13.3.7 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 Rest-of-APAC
  • 13.5 Latin America
    • 13.5.1 Brazil
    • 13.5.2 Rest-of-Latin America
  • 13.6 Rest-of-the-World

14 Company Profiles

  • 14.1 Overview
  • 14.2 AbbVie Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of AbbVie Inc. in Global DNA Damage Response Drugs Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights about Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 AstraZeneca plc
    • 14.3.1 Company Overview
    • 14.3.2 Role of AstraZeneca plc in Global DNA Damage Response Drugs Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights about Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 Bayer AG
    • 14.4.1 Company Overview
    • 14.4.2 Role of Bayer AG in Global DNA Damage Response Drugs Market
    • 14.4.3 Financials
    • 14.4.4 Key Insight about Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 BeiGene, Ltd.
    • 14.5.1 Company Overview
    • 14.5.2 Role of BeiGene, Ltd. in Global DNA Damage Response Drugs Market
    • 14.5.3 Financials
    • 14.5.4 Key Insights about Financial Health of the Company
    • 14.5.5 SWOT Analysis
  • 14.6 Clovis Oncology
    • 14.6.1 Company Overview
    • 14.6.2 Role of Clovis Oncology in Global DNA Damage Response Drugs Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights about Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Debiopharm International SA
    • 14.7.1 Company Overview
    • 14.7.2 Role of Debiopharm International SA in Global DNA Damage Response Drugs Market
    • 14.7.3 SWOT Analysis
  • 14.8 Eli Lilly & Company
    • 14.8.1 Company Overview
    • 14.8.2 Role of Eli Lilly & Company in Global DNA Damage Response Drugs Market
    • 14.8.3 Financials
    • 14.8.4 Key Insights about Financial Health of the Company
    • 14.8.5 SWOT Analysis
  • 14.9 GlaxoSmithKline plc
    • 14.9.1 Company Overview
    • 14.9.2 Role of GlaxoSmithKline plc in Global DNA Damage Response Drugs Market
    • 14.9.3 Financials
    • 14.9.4 Key Insights about Financial Health of the Company
    • 14.9.5 SWOT Analysis
  • 14.1 Merck KGaA
    • 14.10.1 Company Overview
    • 14.10.2 Role of Merck KGaA in Global DNA Damage Response Drugs Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights about Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 NMS Group S.p.A
    • 14.11.1 Company Overview
    • 14.11.2 Role of NMS Group S.p.A in Global DNA Damage Response Drugs Market
    • 14.11.3 SWOT Analysis
  • 14.12 Onxeo SA
    • 14.12.1 Company Overview
    • 14.12.2 Role of Onxeo SA in Global DNA Damage Response Drugs Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights about Financial Health of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 Pfizer Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of Pfizer Inc. in Global DNA Damage Response Drugs Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights about Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Repare Therapeutics
    • 14.14.1 Company Overview
    • 14.14.2 Role of Repare Therapeutics in Global DNA Damage Response Drugs Market
    • 14.14.3 SWOT Analysis
  • 14.15 Sierra Oncology, Inc.
    • 14.15.1 Company Overview
    • 14.15.2 Role of Sierra Oncology, Inc. in Global DNA Damage Response Drugs Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights about Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Zentalis Pharmaceuticals, LLC
    • 14.16.1 Company Overview
    • 14.16.2 Role of Zentalis Pharmaceuticals, LLC in Global DNA Damage Response Drugs Market
    • 14.16.3 SWOT Analysis

List of Figures

  • Figure 1: Global Prevalence of Prostate and Breast Cancer, 2012-2017
  • Figure 2: Steps for Obtaining Marketing Authorization in the U.S.
  • Figure 3: Clinical Landscape of DNA Damage Response Drugs, by Phase of Development
  • Figure 4: Clinical Landscape of DNA Damage Response Drugs, by Pathway Target
  • Figure 5: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
  • Figure 6: Global Target Population of DNA Damage Response Drugs, 2020-2030
  • Figure 7: Impact Analysis of Market Drivers and Market Challenges on the Global DNA Damage Response Drugs Market
  • Figure 8: Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019 vs. 2030 ($Million)
  • Figure 9: Expected Revenue of DNA Damage Response Drugs, by Potential Pipeline Drugs, 2025 vs. 2030
  • Figure 10: Global DNA Damage Response Drugs Market, by Application, 2019 vs. 2030 ($Million)
  • Figure 11: Global DNA Damage Response Drugs Market Snapshot
  • Figure 2.1: Global DNA Damage Response Drugs Market Segmentation
  • Figure 3.1: Global DNA Damage Response Drugs Market: Research Methodology
  • Figure 3.2: Bottom-up Approach (Segment-Wise Analysis)
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Underlying Pathway of DNA Damage and Repair
  • Figure 4.2: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term Implications
  • Figure 4.3: North America DNA Damage Response Drugs Market, 2019 and 2030
  • Figure 4.4: Europe DNA Damage Response Drugs Market, 2019-2030
  • Figure 4.5: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
  • Figure 4.6: Latin America DNA Damage Response Drugs Market, 2019-2030
  • Figure 5.1: Steps for Obtaining Marketing Authorization
  • Figure 5.2: Share of Patents (by Ownership), 2016-2019
  • Figure 6.1: Global Prevalence of Breast, Prostate, and Ovarian Cancer, 2013-2017
  • Figure 7.1: Share of Key Developments and Strategies, January 2016 - May 2020
  • Figure 7.2: Product Approvals and Other Activities Share (by Company), January 2016 - May 2020
  • Figure 7.3: Synergistic Activities Share (by Company), January 2016 - May 2020
  • Figure 7.4: Product Launch and Upgradations Share (by Company), January 2016 - May 2020
  • Figure 7.5: Business Expansion and Funding Share (by Company), January 2016 - May 2020
  • Figure 7.6: Mergers and Acquisitions Share (by Company), January 2016 - May 2020
  • Figure 7.7: Market Share Analysis for Global DNA Damage Response Drugs Market, 2018 and 2019
  • Figure 7.8: Growth-Share Analysis for Global DNA Damage Response Drugs Market, (by Commercialized Drugs), 2019
  • Figure 8.1: Global Prevalence of Ovarian Cancer (2012-2017)
  • Figure 8.2: Global Prevalence of Breast Cancer (2012-2017)
  • Figure 8.3: Global Prevalence of Prostate Cancer (2012-2017)
  • Figure 8.4: Global Prevalence of Pancreatic Cancer (2012-2017)
  • Figure 8.5: Global Target Population of Ovarian Cancer (2020-2030)
  • Figure 8.6: Global Target Population of Breast Cancer (2020-2030)
  • Figure 8.7: Global Target Population of Pancreatic Cancer (2020-2030)
  • Figure 8.8: Global Target Population of Prostate Cancer (2020-2030)
  • Figure 9.1: DNA Damage Response Drugs: Developmental Phases
  • Figure 9.2: DNA Damage Response Drugs, by Pathway Target
  • Figure 9.3: DNA Damage Response Drugs: by Oncology Specialty
  • Figure 10.1: Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019-2030
  • Figure 10.2: Global Revenue for Lynparza, 2019-2030
  • Figure 10.3: Treatment Flow of Lynparza for Each Indication
  • Figure 10.4: Global Revenue for Talzenna, 2019-2030
  • Figure 10.5: Treatment Flow of Talzenna for Each Indication
  • Figure 10.6: Global Revenue for Zejula, 2019-2030
  • Figure 10.7: Treatment Plan of Zejula for Each Indication
  • Figure 10.8: Global Revenue for Rubraca, 2019-2030
  • Figure 10.9: Treatment Plan of Rubraca for Each Indication
  • Figure 11.1: Expected Revenue for Pamiparib (by Late Phase), 2025-2030
  • Figure 11.2: Expected Revenue for Veliparib (by Late Phase), 2025-2030
  • Figure 11.3: Expected Revenue for Fluzoparib (by Late Phase), 2025-2030
  • Figure 12.1: Global DNA Damage Response Drugs Market (by Application)
  • Figure 12.2: Global DNA Damage Response Drugs Market (by Application), 2019-2030
  • Figure 12.3: Global DNA Damage Response Drugs Market (by Ovarian Cancer), 2019-2030
  • Figure 12.4: Global DNA Damage Response Drugs Market (by Breast Cancer), 2019-2030
  • Figure 12.5: Global DNA Damage Response Drugs Market (by Pancreatic Cancer), 2019-2030
  • Figure 12.6: Global DNA Damage Response Drugs Market (by Prostate Cancer), 2019-2030
  • Figure 13.1: Global DNA Damage Response Drugs Market Snapshot (by Region)
  • Figure 13.2: Global DNA Damage Response Drugs Market (by Region), 2019-2030
  • Figure 13.3: Global DNA Damage Response Drugs Market Share (by Region), 2019 and 2030
  • Figure 13.4: North America DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.5: North America: Market Dynamics
  • Figure 13.6: North America DNA Damage Response Drugs Market (by Country), 2019-2030
  • Figure 13.7: U.S. DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.8: Canada DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.9: Europe DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.10: Europe Market Dynamics
  • Figure 13.11: Europe DNA Damage Response Drugs Market (by Country), 2019-2030
  • Figure 13.12: Germany DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.13: France DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.14: U.K. DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.15: Italy DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.16: Spain DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.17: Switzerland DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.18: Rest-of-Europe DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.19: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.20: APAC: Market Dynamics
  • Figure 13.21: APAC DNA Damage Response Drugs Market (by Country), 2019-2030
  • Figure 13.22: China DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.23: Japan DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.24: India DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.25: Australia DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.26: RoAPAC DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.27: Latin America DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.28: Latin America: Market Dynamics
  • Figure 13.29: Latin America DNA Damage Response Drugs Market (by Country), 2019-2030
  • Figure 13.30: Brazil DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.31: Rest-of-Latin America DNA Damage Response Drugs Market, 2019-2030
  • Figure 13.32: RoW DNA Damage Response Drugs Market, 2019-2030
  • Figure 14.1: Total Number of Companies Profiled
  • Figure 14.2: AbbVie Inc.: Pipeline Product Portfolio
  • Figure 14.3: AbbVie Inc.: Overall Financials, 2017-2019
  • Figure 14.4: AbbVie Inc.: Revenue (by Region), 2017-2019
  • Figure 14.5: AbbVie Inc.: R&D Expenditure, 2017-2019
  • Figure 14.6: AbbVie Inc.: SWOT Analysis
  • Figure 14.7: AstraZeneca plc: Overall Product Portfolio
  • Figure 14.8: AstraZeneca plc: Pipeline Product Portfolio
  • Figure 14.9: AstraZeneca plc: Overall Financials, 2017-2019
  • Figure 14.10: AstraZeneca plc: Revenue (by Segment), 2017-2019
  • Figure 14.11: AstraZeneca plc: Revenue (by Region), 2017-2019
  • Figure 14.12: AstraZeneca plc: R&D Expenditure, 2017-2019
  • Figure 14.13: AstraZeneca plc: SWOT Analysis
  • Figure 14.14: Bayer AG: Pipeline Product Portfolio
  • Figure 14.15: Bayer AG: Overall Financials, 2017-2019
  • Figure 14.16: Bayer AG: Revenue (by Segment), 2018-2019
  • Figure 14.17: Bayer AG: Revenue (by Region), 2017-2019
  • Figure 14.18: Bayer AG: R&D Expenditure, 2017-2019
  • Figure 14.19: Bayer AG: SWOT Analysis
  • Figure 14.20: BeiGene, Ltd.: Pipeline Product Portfolio
  • Figure 14.21: BeiGene, Ltd.: Overall Financials: 2017-2019
  • Figure 14.22: BeiGene, Ltd.: Revenue (by Region), 2017-2019
  • Figure 14.23: BeiGene, Ltd.: R&D Expenditure, 2017-2019
  • Figure 14.24: BeiGene, Ltd.: SWOT Analysis
  • Figure 14.25: Clovis Oncology: Overall Product Portfolio
  • Figure 14.26: Clovis Oncology: Pipeline Product Portfolio
  • Figure 14.27: Clovis Oncology: Overall Financials, 2017-2019
  • Figure 14.28: Clovis Oncology: R&D Expenditure, 2017-2019
  • Figure 14.29: Clovis Oncology: SWOT Analysis
  • Figure 14.30: Debiopharm International SA: Pipeline Product Portfolio
  • Figure 14.31: Debiopharm International SA: SWOT Analysis
  • Figure 14.32: Eli Lilly & Company: Pipeline Product Portfolio
  • Figure 14.33: Eli Lilly & Company: Overall Financials, 2017-2019
  • Figure 14.34: Eli Lilly & Company: Revenue (by Region), 2017-2019
  • Figure 14.35: Eli Lilly & Company: SWOT Analysis
  • Figure 14.36: GlaxoSmithKline plc: Overall Product Portfolio
  • Figure 14.37: GlaxoSmithKline plc: Pipeline Product Portfolio
  • Figure 14.38: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 14.39: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 14.40: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 14.41: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 14.42: GlaxoSmithKline plc: SWOT Analysis
  • Figure 14.43: Merck KGaA: Pipeline Product Portfolio
  • Figure 14.44: Merck KGaA: Overall Financials, 2017-2019
  • Figure 14.45: Merck KGaA: Revenue (by Segment), 2017-2019
  • Figure 14.46: Merck KGaA: Revenue (by Region), 2017-2019
  • Figure 14.47: Merck KGaA: R&D Expenditure, 2017-2019
  • Figure 14.48: Merck KGaA: SWOT Analysis
  • Figure 14.49: NMS Group S.p.A: Pipeline Product Portfolio
  • Figure 14.50: NMS Group S.p.A: SWOT Analysis
  • Figure 14.51: Onxeo SA: Pipeline Product Portfolio
  • Figure 14.52: Onxeo SA: Overall Financials, 2017-2019
  • Figure 14.53: Onxeo SA: Revenue (by Segment), 2017-2019
  • Figure 14.54: Onxeo SA: Revenue (by Region), 2017
  • Figure 14.55: Onxeo SA: Revenue (by Region), 2018-2019
  • Figure 14.56: Onxeo SA: R&D Expenditure (by Region), 2018-2019
  • Figure 14.57: Onxeo SA: SWOT Analysis
  • Figure 14.58: Pfizer Inc.: Overall Product Portfolio
  • Figure 14.59: Pfizer Inc.: Pipeline Product Portfolio
  • Figure 14.60: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 14.61: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.62: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 14.63: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 14.64: Pfizer Inc.: R&D Expenditure, 2017-2019
  • Figure 14.65: Pfizer Inc.: SWOT Analysis
  • Figure 14.66: Repare Therapeutics: Pipeline Product Portfolio
  • Figure 14.67: Repare Therapeutics: SWOT Analysis
  • Figure 14.68: Sierra Oncology, Inc.: Pipeline Product Portfolio
  • Figure 14.69: Sierra Oncology, Inc.: Overall Financials, 2017-2019
  • Figure 14.70: Sierra Oncology, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.71: Sierra Oncology, Inc.: SWOT Analysis
  • Figure 14.72: Zentalis Pharmaceuticals, LLC: Pipeline Product Portfolio
  • Figure 14.73: Zentalis Pharmaceuticals, LLC: SWOT Analysis

List of Tables

  • Table 4.1: Approved DNA Damage Response Drugs, May 2020
  • Table 6.1: Impact Analysis of Market Drivers
  • Table 6.2: Impact Analysis of Market Restraints
  • Table 6.3: Comparison of R&D Expenditure of Major Companies in Global DNA Damage Response Drugs Market, $Million, 2019 and 2018
  • Table 8.1: Cancer Types Treated with DNA Damage Response Drugs
  • Table 11.1: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.2: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.3: Pipeline of WEE1 Kinase Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.4: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.5: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.6: Pipeline of Aurora B Kinase Inhibitor in the Global DNA Damage Response Drugs Market
  • Table 11.7: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
  • Table 11.8: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs Market
  • Table 11.9: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 11.10: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market
  • Table 12.1: Marketed DNA Damage Response (DDR) Drugs for Ovarian Cancer
  • Table 12.2: DNA Damage Response (DDR) Drugs for Ovarian Cancer: Pipeline Products
  • Table 12.3: Marketed DNA Damage Response (DDR) Drugs for Breast Cancer
  • Table 12.4: DNA Damage Response (DDR) Drugs for Breast Cancer: Pipeline Products
  • Table 12.5: Marketed DNA Damage Response (DDR) Drugs for Pancreatic Cancer
  • Table 12.6: DNA Damage Response (DDR) Drugs for Pancreatic Cancer: Pipeline Products
  • Table 12.7: Marketed DNA Damage Response (DDR) Drugs for Prostate Cancer
  • Table 12.8: DNA Damage Response (DDR) Drugs for Prostate Cancer: Pipeline Products